Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

How I treat post-immunotherapy relapsed B-ALL

Adam J. Lamble, Alexandra E Kovach, Nirali N Shah

Blood blood.2024024517.

https://doi.org/10.1182/blood.2024024517

Published: 2024

Journal Articles

IFN-γ and CD38 in AML: a T-cell engagement made in heaven?

Adam J. Lamble, Rachel E. Rau

Blood (2024) 143 (16): 1556–1557.

https://doi.org/10.1182/blood.2023023786

Published: 2024

Journal Articles

CREBBP alterations are associated with a poor prognosis in de novo AML

Adam J. Lamble, Kohei Hagiwara, Robert B. Gerbing, Jenny L. Smith, Pandurang Kolekar, Rhonda E. Ries, Edward A. Kolb, Todd A. Alonzo, Xiaotu Ma, Soheil Meshinchi

Blood (2023) 141 (17): 2156–2159.

https://doi.org/10.1182/blood.2022017545

Published: 2023

Includes: Supplemental data

Journal Articles

Pathogenic TP53 mutations Are Associated with a Poor Prognosis in De Novo AML

Adam J. Lamble, Rhonda E. Ries, Alice Dang, Todd A. Alonzo, Karen Chisholm, Pandurang Kolekar, Yanling Liu, Quang Tran, Todd M. Cooper, Richard Aplenc, Alan S. Gamis, Edward A. Kolb, Xiaotu Ma, Soheil Meshinchi

Blood (2022) 140 (Supplement 1): 6297–6298.

https://doi.org/10.1182/blood-2022-162832

Published: 2022

Journal Articles

Phase I Study of Tagraxofusp with or without Chemotherapy in Pediatric Patients with Relapsed or Refractory CD123-Expressing Hematologic Malignancies: A Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium Trial

Adam J. Lamble, Yueh-Yun Chi, Bill H. Chang, Anupam Verma, Kelly E Faulk, Alexandra McLean Stevens, Lauren Pommert, Sarah Tucker, Benjamin Brookhart, Nirali N. Shah, Christopher L. Brooks, Tariq I. Mughal, Alan S. Wayne, Soheil Meshinchi, Todd M. Cooper

Blood (2022) 140 (Supplement 1): 6102–6103.

https://doi.org/10.1182/blood-2022-163503

Published: 2022

Journal Articles

Expanding the High-Risk Definition for Children with Newly Diagnosed Acute Myeloid Leukemia

Adam J. Lamble, Rhonda E. Ries, Todd A. Alonzo, Yi-Cheng Wang, Jason E Farrar, Benjamin J. Huang, Matthew A. Kutny, Jessica A. Pollard, Richard Aplenc, Alan S. Gamis, Edward A. Kolb, Todd M. Cooper, Soheil Meshinchi

Blood (2022) 140 (Supplement 1): 3393–3394.

https://doi.org/10.1182/blood-2022-167680

Published: 2022

Journal Articles

Safety and Activity of Flotetuzumab in Pediatric and Young Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia: Results from the COG PEPN1812 Phase 1 Trial

Adam J. Lamble, Xiaowei Liu, Charles Minard, Olga Militano, Melanie Brooke Bernhardt, Todd M. Cooper, Edward A. Kolb, Erin H. Breese, Elizabeth Fox, Sarah K Tasian, Brenda J. Weigel

Blood (2022) 140 (Supplement 1): 6209–6210.

https://doi.org/10.1182/blood-2022-158029

Published: 2022

Journal Articles

Access to CAR-T Cell Therapy in Underrepresented Populations: A Multicenter Cohort Study of Pediatric and Young Adult ALL Patients

Anurekha G. Hall, Lena E. Winestone, Erin M. Sullivan, Qian Vicky Wu, Adam J. Lamble, Mark C. Walters, Paibel Aguayo-Hiraldo, Lourdes Baez Conde, Tumaini R. Coker, Hema Dave, Dana Dornsife, Amy K. Keating, Diana M. Merino, Bonnie Ramsey, Julie R. Park, Anurag K. Agrawal

Blood (2021) 138 (Supplement 1): 339.

https://doi.org/10.1182/blood-2021-148256

Published: 2021

Journal Articles

KMT2A Rearrangements Are Associated with Lineage Switch Following CD19 Targeting CAR T-Cell Therapy

Blood (2021) 138 (Supplement 1): 256.

https://doi.org/10.1182/blood-2021-153336

Published: 2021

Journal Articles

Crebbp Alterations Are Associated with a Poor Prognosis in De Novo AML

Adam J. Lamble, Robert B. Gerbing, Jenny L. Smith, Rhonda E. Ries, Edward A. Kolb, Todd A. Alonzo, Soheil Meshinchi

Blood (2021) 138 (Supplement 1): 3451.

https://doi.org/10.1182/blood-2021-154052

Published: 2021

Journal Articles

CEBPA -bZip mutations are associated with favorable prognosis in de novo AML: a report from the Children’s Oncology Group

Katherine Tarlock, Adam J. Lamble, Yi-Cheng Wang, Robert B. Gerbing, Rhonda E. Ries, Michael R. Loken, Lisa Eidenschink Brodersen, Laura Pardo, Amanda Leonti, Jenny L. Smith, Tiffany A. Hylkema, William G. Woods, Todd M. Cooper, E. Anders Kolb, Alan S. Gamis, Richard Aplenc, Todd A. Alonzo, Soheil Meshinchi

Blood (2021) 138 (13): 1137–1147.

https://doi.org/10.1182/blood.2020009652

Published: 2021

Includes: Supplemental data

Journal Articles

Distinct Genetic Pathways Define Leukemia Predisposition Versus Adaptive Clonal Hematopoiesis in Shwachman-Diamond Syndrome

Alyssa L. Kennedy, MDPhD, Kasiani C. Myers, MD, James Bowman, PhD, Christopher J. Gibson, MD, Gwen M. Muscato, Robert Klein, Kaitlyn Ballotti, Nicholas Camarda, Elissa M. Furutani, MD, Chad E. Harris, MS, Shanshan Liu, PhD, Ashley Galvin, Maggie Malsch, MSN, RN, David C. Dale, MD, John M Gansner, MD PhD, Taizo A. Nakano, MD, Alison A. Bertuch, MD, Adrianna Vlachos, MD, Jeff H. Lipton, MD PhD, Paul Castillo, MD, James Connelly, John Edwards, MD, Nobuko Hijiya, MD, Richard Ho, MD, Inga Hofmann, MD, James N Huang, MD, Sioban B. Keel, MD, Adam J. Lamble, MD, Bonnie W Lau, MD PhD, Kelly J. Walkovich, MD, Maxim Norkin, MD, Wendy Stock, MD, Steffen Boettcher, Christian Brendel, PhD, Elliot Stieglitz, MD, Mark D. Fleming, MD DPhil, Stella M. Davies, PhD MBBS, MRCP, Edie A. Weller, Chris Bahl, PhD, Scott L. Carter, PhD, Akiko Shimamura, MD PhD, R. Coleman Lindsley, MD PhD

Blood (2020) 136 (Supplement 1): 35–36.

https://doi.org/10.1182/blood-2020-137125

Published: 2020

Journal Articles

Pre-CAR Blinatumomab Is Associated with Increased Post-CD19 CAR Relapse and Decreased Event Free Survival

Agne Taraseviciute, MD, Seth M. Steinberg, PhD, Regina M. Myers, MD, Lia Gore, MD, Adam J. Lamble, MD, Patrick A. Brown, MD, Jennifer Sheppard, Bonnie Yates, NP, Perry Chung, MD, Lee Chen, Colleen Annesley, MD, Deepa Bhojwani, MD, Theodore W. Laetsch, MD, Rebecca A Gardner, MD, Susan R. Rheingold, MD, Michael A Pulsipher, MD, Nirali N. Shah, MD

Blood (2020) 136 (Supplement 1): 13–14.

https://doi.org/10.1182/blood-2020-139260

Published: 2020

Journal Articles

CD22 CAR-T Induces Both CD19 and CD22 Surface Down-Modulation: Defining a Mechanism of Generalized Immune Evasion and the Effects of Epigenetic Modifiers

Lingyan Wang, PhDDVM, Yue Zhang, MS, Eden Anderson, BS, Rajesh Kumar, PhD, Adam J. Lamble, MD, Rimas J Orentas, PhD

Blood (2020) 136 (Supplement 1): 22–23.

https://doi.org/10.1182/blood-2020-134930

Published: 2020

Journal Articles

Correlation of CD123 Expression Level with Disease Characteristics and Outcomes in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group

Adam J. Lamble, MD, Lisa Eidenschink Brodersen, PhD, Todd A. Alonzo, PhD, Jim Wang, Robert B. Gerbing, Laura Pardo, Lillian Sung, MD PhD, Sarah K. Tasian, MD, Todd M Cooper, DO, E. Anders Kolb, MD, Richard Aplenc, MD PhD, Michael R. Loken, PhD, Soheil Meshinchi, MD PhD

Blood (2019) 134 (Supplement_1): 459.

https://doi.org/10.1182/blood-2019-124587

Published: 2019

Journal Articles

Novel CD19t T-Antigen Presenting Cells Expand CD19 CAR T Cells In Vivo

Colleen Annesley, MD, Rebecca Gardner, MD, Ashley Wilson, PhD, Corinne Summers, MD, Adam J. Lamble, MD, Julie Rivers, MD, Qian Vicky Wu, PhD, Adam Brand, Adam Johnson, PhD, Karen Spratt, PhD, Stephanie Mgebroff, Christopher Brown, Catherine Lindgren, Julie R. Park, MD, Michael C. Jensen, MD

Blood (2019) 134 (Supplement_1): 223.

https://doi.org/10.1182/blood-2019-131346

Published: 2019

Journal Articles

Clinical Experience of CAR T Cell Immunotherapy for Relapsed and Refractory Infant ALL Demonstrates Feasibility and Favorable Responses

Colleen Annesley, MD, Corinne Summers, MD, Michael A. Pulsipher, MD, Alan S. Wayne, MD, Julie Rivers, MD, Adam J. Lamble, MD, Ashley Wilson, PhD, Qian Vicky Wu, PhD, Adam Brand, Stephanie Mgebroff, Christopher Brown, Catherine Lindgren, Julie R. Park, MD, Michael C. Jensen, MD, Rebecca Gardner, MD

Blood (2019) 134 (Supplement_1): 3869.

https://doi.org/10.1182/blood-2019-131447

Published: 2019

Journal Articles

Altered T Cell Subsets and Function in Patients with Acute Lymphoblastic Leukemia

Jessica Leonard, MD, Yoko Kosaka, PhD, Matthew T Newman, BS, Adam J. Lamble, MD, Pavani Malla, MS, Brian J. Druker, MD, Jeffrey W. Tyner, PhD, Bill H. Chang, MD PhD, Evan F. Lind, PhD

Blood (2018) 132 (Supplement 1): 1547.

https://doi.org/10.1182/blood-2018-99-119409

Published: 2018

Journal Articles

Novel CD19t T-Antigen Presenting Cells Designed to Re-Activate and Expand CD19 CAR T Cells In Vivo: Early Demonstration of Feasibility and Safety

Colleen Annesley, MD, Rebecca Gardner, MD, Olivia Finney, PhD, Corinne Summers, MD, Adam J. Lamble, MD, Julie Rivers, MD, Adam Johnson, PhD, Karen Spratt, PhD, Stephanie Mgebroff, Christopher Brown, Catherine Lindgren, Julie R. Park, MD, Michael C. Jensen, MD

Blood (2018) 132 (Supplement 1): 4021.

https://doi.org/10.1182/blood-2018-99-112285

Published: 2018

Journal Articles

Immunogenomic Exploration of the Acute Myeloid Leukemia Microenvironment Identifies Determinants of T-Cell Fitness

Lauren K. Brady, PhD, David Soong, PhD, Evan F. Lind, PhD, Yoko Kosaka, PhD, Adam J. Lamble, MD, Michael Schaffer, PhD, Brendan P. Hodkinson, PhD, Clare Lefave, PhD, Ted Laderas, PhD, Shannon K. McWeeney, PhD, Homer Adams, III, PhD, Yann Abraham, PhD, Pegah Safabakhsh, MS, Jeffrey W. Tyner, PhD, Brian J. Druker, MD, Fei Huang, PhD

Blood (2018) 132 (Supplement 1): 2750.

https://doi.org/10.1182/blood-2018-99-118424

Published: 2018

NARROW

How I treat post-immunotherapy relapsed B-ALL

IFN-γ and CD38 in AML: a T-cell engagement made in heaven?

CREBBP alterations are associated with a poor prognosis in de novo AML

Pathogenic TP53 mutations Are Associated with a Poor Prognosis in De Novo AML

Phase I Study of Tagraxofusp with or without Chemotherapy in Pediatric Patients with Relapsed or Refractory CD123-Expressing Hematologic Malignancies: A Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium Trial

Expanding the High-Risk Definition for Children with Newly Diagnosed Acute Myeloid Leukemia

Safety and Activity of Flotetuzumab in Pediatric and Young Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia: Results from the COG PEPN1812 Phase 1 Trial

Access to CAR-T Cell Therapy in Underrepresented Populations: A Multicenter Cohort Study of Pediatric and Young Adult ALL Patients

KMT2A Rearrangements Are Associated with Lineage Switch Following CD19 Targeting CAR T-Cell Therapy

Crebbp Alterations Are Associated with a Poor Prognosis in De Novo AML

CEBPA -bZip mutations are associated with favorable prognosis in de novo AML: a report from the Children’s Oncology Group

Distinct Genetic Pathways Define Leukemia Predisposition Versus Adaptive Clonal Hematopoiesis in Shwachman-Diamond Syndrome

Pre-CAR Blinatumomab Is Associated with Increased Post-CD19 CAR Relapse and Decreased Event Free Survival

CD22 CAR-T Induces Both CD19 and CD22 Surface Down-Modulation: Defining a Mechanism of Generalized Immune Evasion and the Effects of Epigenetic Modifiers

Correlation of CD123 Expression Level with Disease Characteristics and Outcomes in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group

Novel CD19t T-Antigen Presenting Cells Expand CD19 CAR T Cells In Vivo

Clinical Experience of CAR T Cell Immunotherapy for Relapsed and Refractory Infant ALL Demonstrates Feasibility and Favorable Responses

Altered T Cell Subsets and Function in Patients with Acute Lymphoblastic Leukemia

Novel CD19t T-Antigen Presenting Cells Designed to Re-Activate and Expand CD19 CAR T Cells In Vivo: Early Demonstration of Feasibility and Safety

Immunogenomic Exploration of the Acute Myeloid Leukemia Microenvironment Identifies Determinants of T-Cell Fitness

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only